Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

Withdrawn before enrolling · Phase 2

Conditions studied: Heroin Dependence, Opioid-Related Disorders

In brief

The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.

Key facts

Study ID

NCT00000326

Run by

University of Colorado, Denver

People needed

0

Starts

1997-04-01

Expected to finish

1997-08-01

Last updated by the study team

2017-05-04

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals must be currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency.

You may not qualify if…

• Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Where it is running

• University of Colorado Health Sciences Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.